CHARLOTTE, NC--(Marketwire - Aug 8, 2011) - Premier Alliance Group, Inc. (
Mark Elliott, President of Premier, said, "We continue to have good success in providing expertise related to Sarbanes Oxley efforts with existing clients as well as adding new clients that need to meet the regulatory requirements. Our success continues to reinforce our strategy of a right sized approach which leverages our knowledge based expertise in specific sectors including biotechnology and medical devices."
Some of the new business wins include:
- Sarbanes Oxley implementation for a publicly listed medical device company; REVA Medical is an innovative medical device company that utilizes its proprietary coronary stent design and bioresorbable polymer technologies to develop products that improve the treatment of disease and advance patient care.
- Sarbanes Oxley implementation for a biopharmaceutical company; Regulus Therapeutics Inc. is a biopharmaceutical company leading the discovery and development of a new class of high-impact medicines based on microRNAs.
About Premier Alliance Group, Inc.
Premier Alliance Group, Inc. (
Safe Harbor Statement
Certain information contained in this press release may be forward-looking. Actual results might differ materially from any forward-looking statements contained in this press release. Such forward-looking statements involve known and unknown risks, uncertainties and other unknown factors that could cause the actual results of Premier Alliance Group to be materially different from any future results expressed or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates" or "plans" to be uncertain and forward-looking.
Contact Information:
Investor Relations Contact:
Jeff Ramson
ProActive Capital Resources Group
212-792-4321
jramson@proactivecrg.com